NCT05362773 - A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

May 31, 2027

Conditions

Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin LymphomaLeukemia, B-cellLeukemia, Hairy CellMastocytosis, Aggressive SystemicBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid Leukemia

Interventions

DRUG

MGD024

MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.

Trial Locations (7)

21201

RECRUITING

University of Maryland, Greenbaum Comprehensive Cancer Center, Baltimore

27710

RECRUITING

Duke University Medical Center, Durham

49503

RECRUITING

START - Midwest, Grand Rapids

63110

RECRUITING

Washington University School of Medicine, St Louis

78704

RECRUITING

South Austin Medical Center, Austin

80218

RECRUITING

Colorado Blood Cancer Network, Denver

02215

RECRUITING

Dana Farber Cancer Institute, Boston